Costs for acute myocardial infarction in a tertiary care centre and nationwide in france

PharmacoEconomics

Volumn 17, Issue 6, 2000, Pages 603-609

  Montagne, Olivier ^a   Chaix, Carine ^a   Harf, Alain ^a   Castaigne, Alain ^a   Durand Zaleski, Isabelle ^a  

^a HENRI MONDOR HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ACCOUNTING; ACUTE HEART INFARCTION; ANGIOCARDIOGRAPHY; ARTICLE; CORONARY ARTERY SURGERY; FRANCE; HEALTH CARE COST; HOSPITAL ADMISSION; HOSPITAL COST; HUMAN; HUMAN CELL; HUMAN TISSUE; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; REIMBURSEMENT; TECHNOLOGY;

EID: 0034124445     PISSN: 11707690     EISSN: None     Source Type: Journal    
DOI: 10.2165/00019053-200017060-00006     Document Type: Article

References (15)

1. 1. Fielding J, Lancry P-J. Lessons from France: 'vive la différence'. JAMA 1993; 270: 748-56
2. 2. Drummond M, Stoddart G, Torrance G. Checklist of questions to ask when undertaking an economic evaluation. In: Methods for economic evaluation of health care programmes. Oxford: Oxford University Press, 1996: 35-8
3. 3. Russel LB, Gold MR, Siegel JR, et al., for the Panel on Cost-Effectiveness in Health and Medicine. The role of cost-effectiveness analysis in health and medicine. JAMA 1996; 276: 1172-7
4. 4. Weinstein MC, Siegel JE, Gold MR, et al., for the Panel on Cost-Effectiveness in Health and Medicine. Recommendations of the Panel on cost-effectiveness in health and medicine. JAMA 1996; 276: 1253-8
5. 5. Siegel JE, Weinstein MC, Russel LB, et al., for the Panel on Cost-Effectiveness in Health and Medicine. Recommendations for reporting cost-effectiveness analyses. JAMA 1996; 276: 1339-41
6. 6. Haas B, Arveiler D, Cambou JP, et al. Prise en charge thérapeutique de l'infarctus du myocarde: évolution dans le projet MONICA-France entre 1985 et 1991. Rev Epidemiol Sante Publique 1996; 44 Suppl. 1: 53-61
7. 7. Tunstall Pedoe H. Monitoring trends in cardiovascular disease and risk factors: the WHO MONICA project. WHO Chron 1985; 39: 3-5
8. 8. Rabilloud M, Ecochard R, Myard A-F, et al. Impact du mode de recueil des données sur le classement médico-économique des séjours pour infarctus du myocarde aux Hospices Civils de Lyon. Arch Mal Coeur 1998; 91: 709-14
9. 9. Jacobzone S, Dormont B, Durand-Zaleski I. Determinants and consequences of technological change in health care in France: heart attacks. In: McClelland M, editor. Technological change in health care. Chicago (IL): Michigan University Press. In press
10. 10. Mark D, Talley D, Topol E, et al. Economic assessment of platelet glycoprotein IIb/IIIa inhibition for the prevention of high-risk coronary angioplasty. Circulation 1996; 94: 629-35
11. 11. Mark D, Hlatky M, Califf R, et al. Cost-effectiveness of thrombolytic therapy with tissue plasminogen activator as compared with streptokinase for acute myocardial infarction. N Engl J Med 1995; 332: 1418-24
12. 12. Organisation for Economic Co-operation and Development (OECD). The reform of health care systems: a review of seventeen OECD countries. Paris: OECD Publications, 1994
13. 13. Robinson JC, Garnick DW, McPhee SJ. Market and regulatory influences on the availability of coronary angioplasty and bypass surgery in US hospitals. N Engl J Med 1987; 312: 85-90
14. 14. Romeo AA, Wagner J, Lee RH. Prospective reimbursment and the diffusion of new technologies in hospitals. J Health Econ 1984: 3; 1-24
15. 15. Colin C, Ecochard R, Delahaye F. Data quality in a Diagnosis Related Group-based information system. Int J Qual Health Care 1994; 6: 275-80